SK Capital completes sale of Noramco, Extractas Biosciences and Purisys to Siegfried Holding
Monday, May 4, 2026 · first reported by PE Hub
SK Capital divests Noramco, Extractas Biosciences, and Purisys to Siegfried Holding; retains Halo Pharmaceuticals finished-dose-form CDMO.
- Firm
- SK Capital
- Also named
- Siegfried Holding
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore on SK Capital
Everything on this firm →More in Deals
From the same day- Gibson Dunn Represented Related Digital in Joint Venture with Blackstone for the Development and Financing of $16 Billion Hyperscale Data Center Project in Saline Township, MichiganGibson Dunn
- Audax advances bidders into second round of sale process for Nextech, sources sayPE Hub
- Global Net Lease to Acquire Modiv Industrial in $535M MergerCommercial Observer
- Carlyle acquires health tech firms Knack RCM and EqualizeRCMPE Hub
- Gibson Dunn Advises S+S Industries on Strategic Investment in S+S by Cerberus-Managed FundsGibson Dunn
- SE Capital sells HVAC and plumbing firm Sierra Platform to Redwood ServicesPE Hub